---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-22-000029"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:17:17.589207+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Landec reports Q4 net loss $35.9M, announces CEO change and rebranding

## Summary
- Lifecore segment Q4 revenue $27.6M (+6.9% YoY), adjusted EBITDA $8.9M (+15.9%).
- Consolidated Q4 net loss $35.9M includes $27M non-cash impairment on avocado business.
- Full-year Lifecore revenue $109.3M (+11.5%), adjusted EBITDA $28.9M (+17.9%).
- CEO Albert Bolles transitions to President of Curation Foods; James G. Hall named new CEO.
- Plans to rebrand as Lifecore Biomedical, new ticker LFCR; four directors to step down at 2023 meeting.

## SEC filing metadata
- accession: 0001005286-22-000029
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528622000029/0001005286-22-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528622000029/lndc-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-22-000029
- JSON: https://secwatch.observer/filing/0001005286-22-000029.json
- Plain text: https://secwatch.observer/filing/0001005286-22-000029.txt

## Key facts
- Executive change
  Albert Bolles resigned as Chief Executive Officer at LIFECORE BIOMEDICAL, INC. DE.
  - Action: resigned
  - Role: Chief Executive Officer
  source text: In accordance with the Separation Agreement, Dr. Bolles resigned as the Company’s Chief Executive Officer and as a director of the Board of Directors of the Company (the “Board), effective immediately, to transition to serve as President of Curation Foods, Inc., a wholly owned subsidiary of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528622000029/0001005286-22-000029-index.htm
- Executive change
  Deborah Carosella departed as Director at LIFECORE BIOMEDICAL, INC. DE.
  - Action: resign
  - Role: Director
  source text: Deborah Carosella and Tonia Pankopf notified the Company that they each intend to resign as directors of the Board effective as of the 2023 Annual Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528622000029/0001005286-22-000029-index.htm
- Executive change
  James G. Hall was appointed as Chief Executive Officer at LIFECORE BIOMEDICAL, INC. DE.
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On August 10, 2022, the Board appointed James G. Hall as the Company’s Chief Executive Officer and as a director of the Board, succeeding Dr. Albert Bolles, to serve in such capacities until his successor is duly elected and qualified or until his earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528622000029/0001005286-22-000029-index.htm
- Executive change
  Andrew Powell departed as Director at LIFECORE BIOMEDICAL, INC. DE.
  - Action: not stand for re-election
  - Role: Director
  source text: Andrew Powell, and Catherine A. Sohn, Pharm D. notified the Company that they have each elected not to stand for re-election to serve as directors of the Board at the Company’s 2023 annual stockholder meeting (the “ 2023 Annual Meeting ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528622000029/0001005286-22-000029-index.htm
- Executive change
  Tonia Pankopf departed as Director at LIFECORE BIOMEDICAL, INC. DE.
  - Action: resign
  - Role: Director
  source text: Deborah Carosella and Tonia Pankopf notified the Company that they each intend to resign as directors of the Board effective as of the 2023 Annual Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528622000029/0001005286-22-000029-index.htm
- Executive change
  Catherine A. Sohn departed as Director at LIFECORE BIOMEDICAL, INC. DE.
  - Action: not stand for re-election
  - Role: Director
  source text: Andrew Powell, and Catherine A. Sohn, Pharm D. notified the Company that they have each elected not to stand for re-election to serve as directors of the Board at the Company’s 2023 annual stockholder meeting (the “ 2023 Annual Meeting ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528622000029/0001005286-22-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.